
Evidence analysis
Human medicines European public assessment report (EPAR): Remicade, infliximab, Date of authorisation: 13/08/1999, Revision: 70, Status: Authorised
What is established Remicade (active substance infliximab) is a monoclonal antibody medicine authorised in the European Union since 1999. It is used primarily as an anti-inflammatory treatment in several autoimmune diseases where inflammation is pathological, including rheumatoid arthritis,…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Idelvion, albutrepenonacog alfa, Date of authorisation: 11/05/2016, Revision: 14, Status: Authorised
Health & Science Evidence Dossier: Idelvion (albutrepenonacog alfa) for Haemophilia B What is established Idelvion is a medicinal product authorized for use in the European Union to prevent and treat bleeding episodes in patients with haemophilia B, an…
Read →
Evidence analysis
Human medicines European public assessment report (EPAR): Stelara, ustekinumab, Date of authorisation: 16/01/2009, Revision: 54, Status: Authorised
What is established Stelara (ustekinumab) is a monoclonal antibody drug authorized in the European Union since 2009 for the treatment of several inflammatory diseases including moderate to severe plaque psoriasis, active psoriatic arthritis, Crohn’s disease, and ulcerative colitis.…
Read →
Evidence analysis
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 October 2026
What is established In October 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended approval of six new medicines, including treatments for metastatic pancreatic cancer, obesity and type 2 diabetes, achondroplasia in…
Read →
Source briefing
Abusive Care Facility in Thailand Raises Broader Concerns
Click to expand Image A person lies in bed at a nursing home in Ayutthaya, Thailand, April 9, 2016. © 2016 Athit Perawongmetha/Reuters A care facility in Kanchanaburi, Thailand made headlines in early October when photos of conditions in the…
Read →
Source briefing
Associations of food processing and dietary risk factors with colorectal cancer incidence in the NIH-AARP Diet and Health Study: A cohort study
by Leila Abar, Caitlin P. O’Connell, Hyokyoung G. Hong, Kirsten A. Herrick, Lisa Kahle, Jennifer L. Lerman, Linda M. Liao, Xuehong Zhang, Xinyuan Zhang, Longgang Zhao, Sémi Zouiouich, Rashmi Sinha, Neha Khandpur, Eurídice Martínez Steele, Erikka Loftfield Background…
Read →
Source briefing
‘Our focus has been on resiliency.’
University leaders welcome strong financial results, reiterate deep commitment to research in face of ‘substantial and sustained’ challenges
Read →
Source briefing
Human medicines European public assessment report (EPAR): Rasonque, Daraxonrasib, Status: Opinion
Human medicines European public assessment report (EPAR): Rasonque, Daraxonrasib, Status: Opinion
Read →
Source briefing
Human medicines European public assessment report (EPAR): Optruma, raloxifene, Date of authorisation: 05/08/1998, Revision: 28, Status: Withdrawn
Human medicines European public assessment report (EPAR): Optruma, raloxifene, Date of authorisation: 05/08/1998, Revision: 28, Status: Withdrawn
Read →
Source briefing
Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 November 2026, 09:00 (CET) to 20 November 2026, 13:00 (CET)
Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines, Online, European Medicines Agency, Amsterdam, the Netherlands, from 20 November 2026, 09:00 (CET) to 20 November 2026, 13:00 (CET)
Read →